Poniard Pharmaceuticals, Inc, claims that Phase 2 trial study met its primary objective, that is picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI regimen) was associated with a statistically significant reduction in neurotoxicity (p <0.004) compared to oxaliplatin given in combination with 5-fluorouracil and leucovorin (FOLFOX regimen). More...
Med-Chemist : "Quintessential Medicinal Chemistry"
Saturday, January 30, 2010
Positive results from Phase 2 trial of picoplatin for colorectal cancer...
In continuation of my update on picoplatin,.......
